Psilocybin — the ‘magic mushroom’ drug — could see restrictions eased
The arrangement of psilocybin-psychedelic mushrooms “magic” has been a warm issue for California in the years-recent years, but the state deputies flocked attempts to allow the medical use of the substance.
Now change can be at the federal level.
The US Department of Health and Human Services is weighing a petition sent by the Drug Application Administration in the beginning of this month to review scientific evidence and think about alleviating restrictions.
Psilosybin is currently classified as narcotics, which is the most restrictive category reserved for drugs with the potential of abuse ”in accordance with federal laws and olmayan no medical use accepted”. DEA intends to carry Psilosibin to the Less Restrictive Program II layer, which contains addictive or dangerous drugs, including fentanyl and cocaine.
Psilosibin’s efforts to allow the therapeutic use have greatly stopped in the face of the lack of official reconciliation and political will, including California, where there were state deputies. Efforts to blame psilosibin And other psychedelic substances have failed many times.
Despite strict prohibitions under both state and federal laws, psilosibin is widely available and gains popularity for both entertainment and therapeutic purposes.
The illegal marijuana dispensaries in Southern California clearly sell dangerous chocolates and gums, which often claim to contain substance, but also contain only synthetic versions. In recent years, a growing research group has found that psilosibi may be useful in the treatment of mental health conditions such as depression, anxiety and substance use disorder.
Psychedelic access is high on the agenda of Trump’s controversial and conspiracy -minded Health and Human Services Secretary Robert F. Kennedy Jr. Kennedy pointed out the support of expanding access to some hallucinogens in medical environments for the treatment of mental health disorders in the past.
Kennedy’s agency directed all the questions of DEA, who said that he could not comment or confirm about programming actions with an e -mail.
DEA, Dr. After a legal war led by Sunil Aggarwal, Psilocybin sent a petition. For nearly five years, Aggarwal, the co -director of the Advanced Integrative Medical Science Institute in Seattle, has been looking for a tool to obtain and apply psilosibin legally to sick and aging patients in the final stages of their lives.
Aggarwal’s lawyer Kathryn L. Tucker said to Dea that this month, “Psilosibin continues to provide maintenance to patients with advanced and terminal cancer, which can benefit from the supported treatment and provide a more peaceful death process.”
“Science supports the movement to the Program II, and this kind of placement will ensure that the laws that consider early access to promising new drugs for those who have life -threatening conditions will ensure that access to under the right to try.
Aggarwal filed a lawsuit after the 2020 petition to re -plan Psilocybin. A federal panel rejected the case, but the movement towards the re -planning continues because he officially transmitted DEA’s petition to the Health and Human Services Department.
However, some researchers and other experts warn against moving very quickly to expand access.
Dr. Steven Locke wrote the question of whether Psilocybin has any medical practice in an e -mail. Locke, a former president of the American Psychosomatic Association, examined rare situations such as hallucinogen continuing detection disorder, which causes similar symptoms of psilosibin mushrooms and other psychodies.
Locke said, “There is little evidence of good quality studies to support the effectiveness of the use of psilosibin for the treatment of any medical disorder,” Locke said. “Classification must be dependent on a careful examination.”
